Document is current
Any future updates will be listed below
-
Authors
Sang, Shaoming
Pan, Xiaoli
Chen, Zhichun
Zeng, Fan
Pan, Shumei
Liu, Huimin
Jin, Lirong
Fei, Guoqiang
Wang, Changpeng
Ren, Shuhua
Jiao, Fangyang
Bao, Weiqi
Zhou, Weiyan
Guan, Yihui
Zhang, Yiqiu
Shi, Hongcheng
Wang, Yanjiang
Yu, Xiang
Wang, Yun
Zhong, Chunjiu https://orcid.org/0000-0001-7870-3441
-
Funding
Funding for this research was provided by:
the National Natural Science Foundation of China (91332201, 81071019, 81500907, 31471027)
the National Key Research and Development Program Foundation of China (2016YFC1306403)
the Natural Science Foundation of Shanghai (13JC1401501)
-
More Information
Article History
Received: 26 July 2017
Accepted: 5 February 2018
First Online: 1 March 2018
Ethics approval and consent to participate
: This study was approved by the Committee of Medical Ethics of Zhongshan Hospital, Fudan University. All animal care and experimental procedures were approved by the Medical Experimental Animal Administrative Committee of Fudan University and by the Institutional Animals Care and Use Committee of the Institute of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. Informed consent was obtained from all participating subjects.
: Not applicable.
: CJZ holds shares of Shanghai Rixin Bitech Co., Ltd., which is dedicated to developing drugs for preventing and treating AD. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
